The lack of a significant effect of PTEN low on DFS within a treatment regimen was further observed in the North Central Cancer Treatment Group N9831 Intergroup clinical trial that was a Phase III, randomized, three-arm study of adjuvant trastuzumab in HER2-positive early-stage breast cancer. The gene discussed is PTEN; the disease is breast carcinoma.